Auriga Maintains a 'Hold' on United Therapeutics (UTHR); Q4 Review

Auriga maintains a 'Hold' on United Therapeutics (NASDAQ: UTHR) price target of $45.00.

Auriga analyst says, "UTHR reported 4Q11 revenue below both our and the Street estimates. Sales came in lower than we expected, likely reflecting the timing of inventory and quarterly variances in ordering patterns. UTHR
reiterated its prior 2012 and 2013 guidance of $875MM and $1,000MM (both +/- 5%). UTHR has several upcoming catalysts (PDUFA date for oral
Remodulin, EU launch of IV Remodulin, and possible approval in China),
however the current outlook appears to incorporate these items. Given the
limited upside, we maintain our rating."

For an analyst ratings summary and ratings history on United Therapeutics click here. For more ratings news on United Therapeutics click here.

Shares of United Therapeutics closed at $47.58 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• New Street Research Upgrades Micron Technology (MU) to Buy
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald